Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer

作者：Harold J. Burstein, Judith B. Manola, Jerry Younger, Leroy M. Parker, Craig A. Bunnell, Rochelle G. Scheib, Ursula A. Matulonis, Judy Ellen Garber, Kathryn Clarke, Lawrence N. Shulman, Eric P. Winer · 发表于：Journal of Clinical Oncology · 年份：2000 · DOI：10.1200/jco.2000.18.6.1212 · 被引用次数：263 · 研究领域：Cancer Treatment and Pharmacology、Breast Cancer Treatment Studies、Chemotherapy-related skin toxicity

PURPOSE: To evaluate the safety and efficacy of weekly docetaxel in women with metastatic breast cancer. PATIENTS AND METHODS: Twenty-nine women were enrolled onto a study of weekly docetaxel given at 40 mg/m(2)/wk. Each cycle consisted of 6 weeks of therapy followed by a 2-week treatment break, repeated until disease progression or removal from study for toxicity or patient preference. Fifty-two percent of patients had been previously treated with adjuvant chemotherapy; 21% had received prior chemotherapy for metastatic breast cancer, and 31% had previously received anthracyclines. All patients were assessable for toxicity; two patients were not assessable for response but are included in an intent-to-treat analysis. RESULTS: Patients received a median of 18 infusions, with a median cumulative docetaxel dose of 720 mg/m(2). There were no complete responses. Twelve patients had partial responses (overall response rate, 41%; 95% confidence interval, 24% to 61%), all occurring within the first two cycles. Similar response rates were observed among subgroups of patients previously treated either with any prior chemotherapy or with anthracyclines. An additional 17% of patients had stable disease for at least 6 months. The regimen was generally well tolerated. There was no grade 4 toxicity. Only 28% of patients had any grade 3 toxicity, most commonly neutropenia and fatigue. Acute toxicity, including myelosuppression, was mild. Fatigue, fluid retention, and eye tearing/conjunctivi...